tirzepatide under the tongue FDA has approved a new multi-dose KwikPen delivery option for weekly injectable obesity treatment. This label expansion allows patients and providers to choose between: • Single-dose autoinjectors • Multi-dose KwikPen (four Tirzepatide ODT | Empower Pharmacy

Cycle guidelines Cycle guidelines Approach Phase 2 reference Duration 48 weeks Review Point Every 4 weeks at each dose step Best For Matches the original NEJM trial structure Approach Phase 3 TRIUMPH reference Duration 68-72 weeks Review Point Every 4 weeks

Patients with a history of bipolar disorder, severe anxiety, or psychosis might experience worsening of symptoms

Alternatives to Willow worth considering Before committing to Willow, explore these alternatives that may offer better value, better service, or better medications depending on your priorities

This dual incretin signaling is what makes tirzepatide biologically distinct from semaglutide